-
The Expanding Role of CDK 4/6 Inhibitors in Breast Cancer Treatment
31 Jan 2025 18:18 GMT
… of inavolisib (Itovebi; Genentech), palbociclib, and … For endocrine-susceptible breast cancers, the next line … metastatic breast cancer. Presented at: San Antonio Breast Cancer Symposium; … metastatic breast cancer: phase 1b study. NPJ Breast Cancer. 2022 …
-
Kazia Therapeutics Announces The Launch Of A Groundbreaking Trial With Paxalisib In Combination With Immunotherapy In Women With Advanced Breast Cancer
30 Jan 2025 13:27 GMT
… in patients with advanced breast cancer. This novel treatment … type of breast cancer.
The ABC-Pax (Advanced Breast Cancer – Paxalisib) … immunotherapy-resistant triple negative breast cancer. The clinical trial … cancer. Licensed from Genentech in late 2016, …
-
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
29 Jan 2025 01:37 GMT
Genentech Therapeutics’s Phase … 2 negative (HER2) negative breast cancers.
This news comes three months … -positive, HER2-negative, advanced breast cancer.
Primary analysis from the INAVO120 … HR-positive, PIK3CA-mutated breast cancer live longer.”
The INAVO120 …
-
Updated INAVO120 Trial Data Show Overall Survival Improvement with Itovebi Combination in Certain Type of Advanced Breast Cancer
28 Jan 2025 20:21 GMT
… advanced or metastatic breast cancer.1,2 The … locally advanced or metastatic breast cancer: INAVO120, INAVO121, INAVO122 … Locally Advanced or Metastatic Breast Cancer (INAVO120). ClinicalTrials. … -Negative Breast Cancer With a PIK3CA Mutation. Genentech. October …
-
Breast Cancer Market To Reach USD 49.2 Billion By 2032 | AstraZeneca, Pfizer Inc., Merck & Co, Sanofi, Novartis AG
28 Jan 2025 11:13 GMT
… Breast Cancer's Global Impact: Breast cancer … Breast Cancer
The increasing prevalence of breast cancer … breast cancer.
Key Objectives Of The Breast Cancer Global Market:
To analyze the global Breast Cancer … and Company
• Genentech
• Other Key …
-
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
28 Jan 2025 06:16 GMT
… breast cancer
HR-positive breast cancer is the most prevalent type of all breast cancers … .
About Genentech in Breast Cancer
Genentech has been advancing breast cancer research for … breast cancer, the most prevalent type of all breast cancers.
About Genentech …
-
Tucatinib in Combination With Trastuzumab Demonstrates Safety, Efficacy in Patients With HER2-Mutated Breast Cancer
27 Jan 2025 15:42 GMT
… and trastuzumab (Herceptin; Genentech) demonstrated clinically meaningful antitumor … (HER2)-mutated metastatic breast cancer (MBC).
Mutations in … HER2-mutated metastatic breast cancer: a phase 2 … with advanced HER2+ breast cancer (HER2CLIMB). Updated August …
-
Adjuvant Trastuzumab Emtansine Improves Invasive Disease-Free Survival in Patients with HER2+ Early Breast Cancer
24 Jan 2025 23:48 GMT
… (T-DM1, Kadcyla; Genentech) demonstrated improved overall survival ( … 2–positive (HER2+) early breast cancer (EBC). The data, published … patients with HER2-positive breast cancer who have residual tumor … in residual HER2-positive breast cancer. N J Engl Med …
-
Neoadjuvant Atezolizumab Plus Epirubicin Shows Safety, Efficacy in Treatment of HER2+ Early Breast Cancer
24 Jan 2025 18:47 GMT
… based chemotherapy.1
HER2+ breast cancer (BC) subtypes are … with trastuzumab (Herceptin; Genentech), pertuzumab (Perjeta; Genentech), atezolizumab, and epirubicin … modern immunotherapy to optimize breast cancer treatment—through improved effectiveness …
-
FDA Sheds Light on New Drug Approvals in Breast Cancer
24 Jan 2025 18:48 GMT
… (NCT04191499), which studied inavolisib (Itovebi; Genentech, Inc) vs placebo in combination … optimization in breast cancer clinical trials. Presented at: San Antonio Breast Cancer Symposium; December …
About
© 1995-2025